analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
Published 3 years ago • 111 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:44
an update on imetelstat in r/r myelofibrosis
-
7:42
phase ii trial of bomedemstat for advanced myelofibrosis
-
12:33
3mensio ct pre-case planning: valve-in-valve tavr in epic/biocor
-
14:08
low-risk and high-risk mds
-
3:30
unmet needs in mf: managing anemia & improving the efficacy of first and second-line treatments
-
2:57
novel targeted therapies for the treatment of bpdcn
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
0:47
overview of the phase iii enhance trial schema
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:58
novel myelofibrosis-associated anemia treatments in phase ii trials
-
2:04
phase i/ii study of a novel bet inhibitor, bms-986158, alone & with ruxolitinib or fedratinib in mf
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:45
a phase ii study of elritercept for lower-risk mds